#USA #Boston #CereVasc #eShunt #Hydrocephalus

CereVasc, Inc. Marks 100th Patient Treated with eShunt System

CereVasc, Inc., a clinical-stage medical device company focused on innovations in treating neurological diseases, recently celebrated the significant milestone of treating its 100th patient with the innovative eShunt System. This groundbreaking device addresses communicating hydrocephalus, a condition commonly affecting older adults, and represents a significant advancement in neurovascular treatment facilities.

On July 30, 2025, Dr. Pedro Lylyk at Clinica la Sagrada Familia in Buenos Aires, Argentina, performed this landmark procedure. Dr. Lylyk, who notably also treated the very first patient with the eShunt System, expressed his honor at reaching this milestone. He emphasized the importance of the eShunt System for broadening treatment options for patients suffering from hydrocephalus, noting that its minimally invasive approach drastically increases the number of patients eligible for necessary surgery.

The eShunt System is heralded as the first of its kind, providing a minimally invasive, endovascular solution to hydrocephalus – a serious condition where excess cerebrospinal fluid collects in the brain, causing various cognitive and mobility issues. Prior to the eShunt, ventriculo-peritoneal (VP) shunts were the standard treatment option, a method that had remained unchanged for over six decades.

The eShunt's design allows for a novel procedure that utilizes a percutaneous transvenous-transdural access route, enabling the device to function inside the body without extensive surgical intervention. The device's breakthrough design is a collaboration between leading neurosurgeons and innovators at Tufts Medical Center, aiming to improve the efficacy and safety of treating patients who suffer from conditions like Normal Pressure Hydrocephalus (NPH), which often goes undiagnosed or misdiagnosed due to symptom similarities with Alzheimer’s or Parkinson’s diseases.

As part of a pivotal clinical trial, known as STRIDE, the eShunt System was put to the test against the traditional VP shunt to determine its effectiveness. The study, which began with a concentration on clinical performance, aims to substantiate the eShunt's viability as a new treatment option and to gain regulatory approval for broader market distribution.

CereVasc's CEO, Dan Levangie, lauded the collaboration between clinical specialists like Dr. Lylyk and the company, attributing the success of reaching this milestone to the combined commitment to advancing medical technology. With strong enrollment numbers reported for the STRIDE trial, CereVasc shows promise not only in expanding treatment options for patients but also in setting new standards for surgical interventions in neurology.

The eShunt System represents a crucial development in medical device technology intended to alleviate the burdens of communicating hydrocephalus. According to the Hydrocephalus Association, an estimated 800,000 older Americans could be living with NPH, with a staggering 80% of these cases remaining untreated. The implications of the eShunt System are thus monumental, potentially shifting the paradigm in treatment approaches for a forgotten cohort of patients suffering from this condition.

Despite the promising advancements, the eShunt remains an investigational device, and its safety and effectiveness are yet to be fully validated by regulatory bodies. Therefore, the medical community looks forward to the outcomes of ongoing studies and seeks to ensure that patients suffering from hydrocephalus will receive the care they need.

For further information regarding the eShunt System and the ongoing clinical trials, interested parties can visit CereVasc's official website or the dedicated STRIDE study page at https//nphstridestudy.com/.

With innovations like the eShunt, the future looks promising for both patients and practitioners navigating the complexities of hydrocephalus treatment, reflecting a necessary evolution in medical practice toward less invasive solutions and more effective patient care.